13F filer · CIK 1652044 ↗

Alphabet Inc.

You are looking at Q3 2025. See the latest, Q2 2026 →

Reported value

$2.41B

+13% on the quarter before

Positions

2 new · 1 sold out

Top 10

89.1%

of the value

Est. gain

+$391.3M

on stocks held all quarter

Est. return

+19.9%

on those stocks since Q2 2025

Filed

Nov 7, 2025

On SEC EDGAR ↗

Positions as of Sep 30, 2025, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

New
Added
Cut
Same
Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q2 2025. Striped tiles are options.

Ast Spacemobile Inc18%

Planet Labs Pbc17%

Arm Holdings Plc12%

Metsera Inc8.2%

Revolution Medicines Inc8.0%

Freshworks Inc7.9%

Tempus AI5.2%

Gitlab Inc5.1%

UiPath3.9%

Prime Medicine Inc3.8%

Dexcom Inc2.9%

Maze Therapeutics Inc2.6%

Bridgebio Oncology Therapeut1.4%

0.6%

0.5%

Ast Spacemobile Inc18%

Planet Labs Pbc17%

Arm Holdings Plc12%

Metsera Inc8.2%

Revolution Medicines Inc8.0%

Freshworks Inc7.9%

Tempus AI5.2%

Gitlab Inc5.1%

UiPath3.9%

Prime Medicine Inc3.8%

Dexcom Inc2.9%

Maze Therapeutics Inc2.6%

Bridgebio Oncology Therapeut1.4%

0.6%

0.5%

Largest buys

Since Q2 2025, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Bridgebio Oncology Therapeut~$32.7MNew · 0.0% → 1.4%+2,823,126 shares
Figma Inc~$11.2MNew · 0.0% → 0.5%+215,582 shares
Prime Medicine Inc~$8.3MAdded · 1.7% → 3.8%+1,500,000 shares

Largest sells

Since Q2 2025, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Verve Therapeutics Inc~$136.7MSold out · 6.4% → 0.0%−12,168,489 shares
Metsera Inc~$61.7MCut · 6.6% → 8.2%−1,178,216 shares

Holdings

As of Sep 30, 2025. Changes are in shares against Jun 30, 2025, so a price move alone never reads as a buy or a sale.

Positions, sorted by share of the portfolio
#	Holding		% prev	Value	Shares		Price	Prev price
1	Ast Spacemobile IncCOM CL A · shares 0% · price +5.0%	18.2%	19.6%	$438.9M	8.9M	0%	$49.08	$46.73	+5.0%	+$21.0M
2	Planet Labs PbcCOM CL A · shares 0% · price +112.8%	17.2%	9.1%	$414.6M	31.9M	0%	$12.98	$6.10	+112.8%	+$219.8M
3	Arm Holdings PlcSPONSORED ADS · shares 0% · price −12.5%	11.5%	14.9%	$277.4M	2.0M	0%	$141.49	$161.74	−12.5%	−$39.7M
4	Metsera IncCOM · shares −24% · price +83.9%	8.2%	6.6%	$198.0M	3.8M	−24%	$52.33	$28.45	+83.9%	+$90.4M
5	Revolution Medicines IncCOM · shares 0% · price +26.9%	8.0%	7.1%	$193.0M	4.1M	0%	$46.70	$36.79	+26.9%	+$41.0M
6	Freshworks IncCLASS A COM · shares 0% · price −21.1%	7.9%	11.3%	$190.8M	16.2M	0%	$11.77	$14.91	−21.1%	−$50.9M
7	Tempus AICL A · shares 0% · price +27.0%	5.2%	4.6%	$125.2M	1.6M	0%	$80.71	$63.54	+27.0%	+$26.6M
8	Gitlab IncCLASS A COM · shares 0% · price −0.1%	5.1%	5.8%	$122.8M	2.7M	0%	$45.08	$45.11	−0.1%	−$81,741
9	UiPathCL A · shares 0% · price +4.5%	3.9%	4.2%	$94.1M	7.0M	0%	$13.38	$12.80	+4.5%	+$4.1M
10	Prime Medicine IncCOM · shares +10.0% · price +124.3%	3.8%	1.7%	$91.8M	16.6M	+10.0%	$5.54	$2.47	+124.3%	+$46.2M
11	Dexcom IncCOM · shares 0% · price −22.9%	2.9%	4.2%	$69.8M	1.0M	0%	$67.29	$87.29	−22.9%	−$20.7M
12	Maze Therapeutics IncCOM · shares 0% · price +111.3%	2.6%	1.4%	$62.6M	2.4M	0%	$25.93	$12.27	+111.3%	+$33.0M
13	Bridgebio Oncology TherapeutCOM NEW · shares New	1.4%	—	$32.7M	2.8M	New	$11.58	—	—	—
14	Figma IncCLASS A COM STK · shares New	0.46%	—	$11.2M	215,582	New	$51.87	—	—	—
15	Monte Rosa Therapeutics IncCOM · shares 0% · price +64.3%	0.45%	0.31%	$10.8M	1.5M	0%	$7.41	$4.51	+64.3%	+$4.2M
16	Sana Biotechnology IncCOM · shares 0% · price +30.0%	0.41%	0.36%	$10.0M	2.8M	0%	$3.55	$2.73	+30.0%	+$2.3M
17	Oscar Health IncCL A · shares 0% · price −11.7%	0.38%	0.48%	$9.1M	481,988	0%	$18.93	$21.44	−11.7%	−$1.2M
18	Dianthus Therapeutics IncCOM · shares 0% · price +111.2%	0.34%	0.18%	$8.2M	208,697	0%	$39.35	$18.63	+111.2%	+$4.3M
19	Relay Therapeutics IncCOM · shares 0% · price +50.9%	0.34%	0.25%	$8.2M	1.6M	0%	$5.22	$3.46	+50.9%	+$2.8M
20	Beam Therapeutics IncCOM · shares 0% · price +42.7%	0.32%	0.26%	$7.8M	321,604	0%	$24.27	$17.01	+42.7%	+$2.3M
21	Vera Therapeutics IncCL A · shares 0% · price +23.3%	0.29%	0.27%	$7.0M	241,264	0%	$29.06	$23.56	+23.3%	+$1.3M
22	Lyell Immunopharma IncCOM NEW · shares 0% · price +83.7%	0.20%	0.12%	$4.8M	293,256	0%	$16.24	$8.84	+83.7%	+$2.2M
23	Foghorn Therapeutics IncCOM · shares 0% · price +4.0%	0.10%	0.11%	$2.4M	500,901	0%	$4.89	$4.70	+4.0%	+$95,171
24	Genedx Holdings CorpCOM · shares 0% · price +16.7%	0.10%	0.10%	$2.4M	22,711	0%	$107.74	$92.31	+16.7%	+$350,431
25	Taysha Gene Therapies IncCOM SHS · shares 0% · price +41.6%	0.09%	0.07%	$2.1M	640,882	0%	$3.27	$2.31	+41.6%	+$615,247
	Total · 37 positions	100%		$2.41B						+$391.3M

The filing on SEC EDGAR ↗

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q2 2025 to Q3 2025: 35 stocks held throughout, up $391.3M (+19.9%).

Planet Labs Pbc+$219.8M+113%
Metsera Inc+$90.4M+84%
Prime Medicine Inc+$46.2M+124%
Revolution Medicines Inc+$41.0M+27%
Maze Therapeutics Inc+$33.0M+111%
Spero Therapeutics Inc−$907,778−35%
Oscar Health Inc−$1.2M−12%
Dexcom Inc−$20.7M−23%
Arm Holdings Plc−$39.7M−13%
Freshworks Inc−$50.9M−21%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.

$110.00B$55.00B$0

Q1 201642 quartersQ2 2026

Every quarter's filing

Each quarter's 13F filing, newest first
Quarter	Filed	Reported value	Positions	Filing
Q2 2026	Aug 7, 2026	$99.08B+2,367%	28	SEC ↗
Q1 2026	May 8, 2026	$4.02B+56%	26	SEC ↗
Q4 2025	Feb 13, 2026	$2.58B+7%	29	SEC ↗
Q3 2025	Nov 7, 2025	$2.41B+13%	37	SEC ↗
Q2 2025	Aug 1, 2025	$2.14B+35%	36	SEC ↗
Q1 2025	May 2, 2025	$1.58B−8%	40	SEC ↗
Q4 2024	Feb 7, 2025	$1.72B−7%	40	SEC ↗
Q3 2024	Nov 8, 2024	$1.84B−7%	42	SEC ↗
Q2 2024	Aug 2, 2024	$1.97B−21%	42	SEC ↗
Q1 2024	May 3, 2024	$2.51B+17%	43	SEC ↗
Q4 2023	Feb 9, 2024	$2.16B+39%	44	SEC ↗
Q3 2023	Nov 13, 2023	$1.56B−16%	45	SEC ↗
Q2 2023	Aug 4, 2023	$1.86B+3%	47	SEC ↗
Q1 2023	May 11, 2023	$1.80B+5%	49	SEC ↗
Q4 2022	Feb 14, 2023	$1.72B−12%	51	SEC ↗
Q3 2022	Nov 15, 2022	$1.96B+6%	49	SEC ↗
Q2 2022	Nov 15, 2022	$1.84B−40%	55	SEC ↗
Q1 2022	Nov 15, 2022	$3.08B−26%	60	SEC ↗
Q4 2021	Nov 15, 2022	$4.14B−2%	58	SEC ↗
Q3 2021	Nov 15, 2022	$4.22B−14%	43	SEC ↗
Q2 2021	Nov 15, 2022	$4.91B+98%	36	SEC ↗
Q1 2021	Nov 15, 2022	$2.48B+19%	32	SEC ↗
Q4 2020	Nov 15, 2022	$2.08B−2%	31	SEC ↗
Q3 2020	Nov 15, 2022	$2.13B−2%	24	SEC ↗
Q2 2020	Nov 15, 2022	$2.17B+42%	24	SEC ↗
Q1 2020	Nov 15, 2022	$1.52B−8%	25	SEC ↗
Q4 2019	Nov 15, 2022	$1.65B−50%	24	SEC ↗
Q3 2019	Nov 15, 2022	$3.33B−37%	24	SEC ↗
Q2 2019	Nov 15, 2022	$5.27B+172%	22	SEC ↗
Q1 2019	Nov 15, 2022	$1.94B+129%	17	SEC ↗
Q4 2018	Nov 15, 2022	$845.8M−19%	17	SEC ↗
Q3 2018	Nov 15, 2022	$1.04B−12%	17	SEC ↗
Q2 2018	Nov 15, 2022	$1.19B+94%	17	SEC ↗
Q1 2018	Nov 15, 2022	$614.8M+67%	11	SEC ↗
Q4 2017	Nov 15, 2022	$368.6M+7%	8	SEC ↗
Q3 2017	Nov 15, 2022	$344.0M−1%	4	SEC ↗
Q2 2017	Nov 15, 2022	$347.4M+10%	4	SEC ↗
Q1 2017	Nov 15, 2022	$316.8M+8%	3	SEC ↗
Q4 2016	Nov 15, 2022	$292.8M+6%	2	SEC ↗
Q3 2016	Nov 15, 2022	$275.2M+31%	2	SEC ↗
Q2 2016	Nov 15, 2022	$209.8M−14%	3	SEC ↗
Q1 2016	Nov 15, 2022	$242.9M	5	SEC ↗